A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.

Slides:



Advertisements
Similar presentations
SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
Advanced Angioplasty 2008 London Sequent Paclitaxel-Elutng Balloon Scientific Program Wolfgang Bocksch,M.D.,PhD. Director Cardiac Catheterization.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Neointimal Modification with Scoring-Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients with Restenosis in Drug- Eluting Coronary Stents Deutsches.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Drug Eluting Balloon in Acute Myocardial Infarction: (PI) On behalf of the DEB-AMI study group (PI) P.R. Stella, MD, PhD 6 month.
Compare Trial 2 year follow-up Peter Smits Maasstad Ziekenhuis Rotterdam The Netherlands.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
David E. Kandzari, MD on behalf of the BIONICS investigators
DCB for In-Stent Restenosis: Is It Superior to DES?
ISAR-TEST-2 Trial Two-year Clinical and Angiographic Outcomes from a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents versus Polymer-Based Cypher.
The Tryton Bifurcation Trial:
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
OCT-Guided PCI What needs to be done to establish criteria?
A Randomized, Prospective, Intercontinental Evaluation of a Bioresorbable Polymer Sirolimus-eluting Stent: the CENTURY II Trial: an Update with 2 Years.
REALITY: 8 month results
Giuseppe Biondi Zoccai, MD
Kyoto University Hospital, Japan
3-Year Clinical Outcomes From the RESOLUTE US Study
The American College of Cardiology Presented by Dr. Raimund Erbel
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
The American College of Cardiology Presented by Dr. A. Abazid
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES Study Harald Rittger, MD University of Erlangen; Klinikum Coburg Germany TCT 2011 – First Report Investigation KLINIKUM CO B U R G

Disclosures Supported in part by an unrestricted grant by B.Braun, Melsungen, Germany Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit B.Braun, Siemens none None none Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial RelationshipCompany

Centers Harald Rittger, MD Klinikum Coburg Marc-A. Ohlow, MD Zentralklinik Bad Berka Andreas Brugger, MD Klinikum Kulmbach Holger Thiele, MD Herzzentrum Leipzig Ralf Birkemeyer, MD Klinikum Villingen-S. Volker Kurowski, MD Universität Lübeck

Background Drug-eluting stents (DES) significantly reduced the occurrence of restenosis and the subsequent need for repeat revascularization. Nevertheless, the incidence of DES-restenosis (DES-ISR) remains frequent due to the continuous increase in DES implantations.

Background Complex lesions with a high restenotic potential are sufficiently treated with present DES, limiting the use of bare-metal stents (BMS) to patients not eligible for dual antiplatelet therapy. Paclitaxel coated balloon angioplasty (SeQuent Please, B.Braun) has been shown to be superior to plain old balloon angioplasty (POBA) and non-inferior to paclitaxel eluting stent (PES) implantation for treatment of BMS restenosis.

Background Whether the use of paclitaxel coated balloon angioplasty is also effective in DES restenosis has not been sufficiently studied so far. We evaluated in a randomized, multicenter, single blinded trial the efficacy of paclitaxel coated balloon angioplasty (SeQuent Please, B.Braun, Germany) compared with plain old balloon angioplasty for DES restenosis in native coronary arteries.

Inclusion Criteria Age > 18 years Lesion in native coronary artery DES restenosis of  Sirolimus eluting stents: Cypher, Yukon  Everolimus eluting stents: Xience, Promus  Paclitaxel eluting stents: Taxus Indication for PCI (symptoms, ischemia) Reference diameter 2.5 – 3.5 mm Lesion length ≤ 22 mm

Exclusion Criteria thrombus within the target vessel side branch ≥ 2 mm in diameter originating within the restenosis or bifurcation lesion multiple lesions in the target vessel lesions in bypass grafts total coronary artery occlusion lesions within 1 mm of vessel origin or left main planned surgery within 6 months after the index procedure women with childbearing potential contraindication or known hypersensitivity to acetylsalicylic acid, clopidogrel, paclitaxel or heparin.

Primary Endpoint Primary endpoint: six-months late lumen loss at the target lesion. Superiority testing of the primary end point on an intention- to-treat basis.

Primary Endpoint With an assumed late lumen loss of 0.20±0.30mm in the drug coated balloon group and 0.80±0.80mm in the POBA group the necessary number of patients were 64 in the drug coated balloon and 34 in the POBA group to achieve 90% power With an assumed dropout rate of 10% the patient numbers to be recruited were 71 in the drug coated balloon and 38 in the POBA group.

Secondary Endpoints Secondary angiographic endpoints  Binary restenosis, minimal lumen diameter, percent diameter stenosis (target lesion and total segment) Secondary clinical endpoints (definition according to ARC criteria)  Target lesion revascularization  Myocardial infarction  Death  MACE as a composite of cardiac death, myocardial infarction attributable to target vessel, target lesion revascularization

110 patients enrolled and randomized (2:1) 110 patients enrolled and randomized (2:1) Paclitaxel coated balloon N=72 Paclitaxel coated balloon N=72 Ballon angioplasty alone N=38 Ballon angioplasty alone N=38 6 months angiographic follow-up 88.9% (N=64/72) 6 months angiographic follow-up 88.9% (N=64/72) 6 months angiographic follow-up 81.6 % (N=31/38) 6 months angiographic follow-up 81.6 % (N=31/38) 6-month clinical follow-up 100 % (N=72/72) 6-month clinical follow-up 100 % (N=72/72) 6-month clinical follow-up 100 % (N=38/38) 6-month clinical follow-up 100 % (N=38/38) 6 months ASS+Clopidogrel predilation

Baseline Characteristics DCBPOBA Number of patients7238 Age (years)69.8±10.8 *64.0±11.3 Male52 (72.2%)26 (68.4%) Diabetes26 (36.1%)13 (34.2%) Hypertension68 (94.4%)36 (94.7%) Hyperlipidemia59 (81.9%)27 (71.1%) History of smoking11 (15.3%)6 (15.8%) BMI – kg/m ± ±3.5 * p=0.02

Baseline Angiography DCBPOBA Lesion location LAD24 (33.3%)16 (39.0%) CX23 (32.0%)+3 (4.9%) RCA25 (34.7%)19 (46.3%) QCA RVD (mm)2.29± ±0.52 MLD (mm)0.66± ±0.44 % DS72.1± ±16.2 Lesion length (mm) 11.2± ±8.2 + p=0.005

DCBPOBA Pre-dilatation balloon Length (mm)16.0± ±5.5 Diameter (mm)2.84± ±0.34 Inflation Time (sec)39.4± ±16.9 Pressure (bar)15.1± ±3.4 Procedural Data

DCBPOBA Study Balloon Length (mm)21.6±6.4*18.9±6 Diameter (mm)2.95± ±0.39 Inflation Time (sec)57.6± ±17.3 Pressure (bar)14.0± ±5.3 Procedural Data * p=0.041

DCBPOBA RD (mm) 2.47± ±0.58 MLD (mm) Target lesion2.15± ±0.53 Diameter stenosis (%) Target lesion12.6± ±6.0 Post Procedure QCA

Primary Endpoint - Late Loss POBA 1.03 ± 0.77

Primary Endpoint - Late Loss POBADCB 1.03 ± ± 0.61 P < 0.001

P = 0.18 P < P = <0.001 P < Late Loss at 6 Months POBADCB

POBAP Value Target lesion MLD1.75± ±0.73< % DS29.6± ±31.0< Total segment MLD1.65± ±0.68< % DS32.3± ±29.4< Follow-up QCA

P < Binary Angiographic Restenosis at 6 Months Binary Restenosis (%) POBADCB

POBAP Value Target lesion revascularization 11 (15.3 %)14 (36.8 %)0.005 Myocardial infarction Non-target vessel0 (0%) -- Target vessel0 (0 %)1 (2.6 %)0.345 Cardiac Death1 (1.4%)4 (10.5 %)0.048 MACE *12 (16.7 %)19 (50.0 %)<0.001 Clinical Outcomes at 6 Months *TLR, myocardial infarction attributable to target vessel, cardiac death

Conclusion In this prospective, randomized, single-blind, multicenter study the treatment strategy with paclitaxel coated balloon (SeQuent Please, B.Braun) compared with balloon angioplasty alone for treatment of DES restenosis showed: –a significantly lower late loss (primary endpoint) –a significantly lower binary restenosis rate, percent diameter stenosis and a significantly larger minimal lumen diameter at follow-up – significantly less MACE –no definite vessel thrombosis

A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Restenosis of Drug-Eluting Stents PEPCAD-DES Study Harald Rittger, MD University of Erlangen; Klinikum Coburg Germany TCT 2011 – First Report Investigation KLINIKUM CO B U R G Thank you very much for your attention! for your attention!